The therapeutic utility of Ulcerid is commonly used in the symptomatic management of conditions characterized by heightened physiological activity, which contributes to easing the overall symptom load and assists with the healing of tissues.

Ulcerid is commonly used to help with conditions characterized by heightened physiological activity, and provides support that helps ease the overall symptom burden. It may assist with the symptomatic management of heartburn, sour stomach, acid indigestion, Gastroesophageal Reflux Disease (GERD), and ulcers of the stomach and intestines.

---

Relief for Acute Symptoms and Chronic Management

The medication is applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative processes. This includes addressing symptoms related to physical discomfort during acute episodes and supporting patients in long-term management scenarios.

“It is considered relevant for managing symptoms associated with recurrent or episodic manifestations.”

Ulcerid is relevant for easing challenging symptoms associated with active lesions and in contexts requiring sustained control, such as maintenance therapy in situations involving recurrent or episodic manifestations. Furthermore, it is commonly used for pediatric patients to address GERD symptoms. This therapeutic benefit helps maintain a sense of stability when symptoms are more noticeable, contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Heartburn
Applied in clinical settings that involve acute or unstable symptom patterns, especially when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Ulcerid?

This section describes the official population eligibility rules for Ulcerid (Famotidine) as established by regulatory authorities.

---

Eligibility and Exclusion Rules

Population Group	Regulatory Status
Absolute Contraindication	Patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or to any other H2-receptor antagonist must not use this medicine.
Adults	Use is established and approved for all labeled indications.
Children/Adolescents	Use is approved for pediatric patients weighing 40 kg or greater. The 20 mg and 40 mg tablets are not recommended for those weighing less than 40 kg.
Renal Impairment	Patients with moderate or severe renal impairment require conditional use and often a dosage adjustment due to the increased risk of drug accumulation and potential CNS adverse reactions.
Older Adults (Geriatric)	Use requires monitoring of renal function due to an increased risk of CNS adverse reactions.
Pregnancy Status	Classified as Pregnancy Category B; use may be considered if clearly needed.
Lactation Status	Famotidine is detectable in breast milk; a decision to discontinue the drug or breastfeeding may be necessary.

---

Comorbidity Constraint

Before treating gastric ulcer symptoms, the presence of gastric malignancy must be excluded, as symptomatic relief provided by Ulcerid does not rule out underlying cancer.

Ulcerid's official interaction profile is defined by pharmacokinetic and pharmacodynamic patterns documented in regulatory sources.

The primary pharmacokinetic interaction is the reduction of gastric acidity, which can significantly lower the systemic exposure of other orally administered medicines dependent on an acidic environment for absorption. This includes specific medications such as azole antifungals (e.g., Ketoconazole), certain HIV protease inhibitors (e.g., Atazanavir), and several tyrosine kinase inhibitors (e.g., Dasatinib), potentially leading to a loss of therapeutic effect.

A specific metabolic interaction involves the drug Tizanidine. Because Famotidine acts as a weak inhibitor of the CYP1A2 enzyme, co-administration results in a substantial increase in Tizanidine blood concentrations. Regulatory labels mandate that this combination be avoided, if possible. Furthermore, co-administration with Probenecid is documented to increase Famotidine’s own systemic exposure by inhibiting its renal clearance via Organic Anion Transporters (OAT).

For pharmacodynamic interaction, co-administration with other Histamine H2-receptor antagonists is formally contraindicated. Specific timing requirements exist for administration, such as taking the non-prescription formulation 10 to 60 minutes before consuming food or beverages known to cause symptoms. Lastly, patients who are elderly or have moderate to severe renal impairment experience higher systemic exposure to Famotidine, which is associated with increased risk of specific reactions.

Ulcerid (Famotidine) acts exclusively through pharmacodynamic mechanisms to suppress the production of acid in the stomach. The drug functions as a competitive antagonist, selectively targeting the Histamine H2 receptors ( H2 R) found on the basolateral membrane of the gastric parietal cells. By binding to these receptors, Famotidine prevents the body’s natural signaling molecule, Histamine, from activating the cell.

This H2 R blockade immediately interrupts the intracellular signaling cascade. Receptor activation typically stimulates the enzyme adenylate cyclase, leading to an increase in cAMP and subsequent Protein Kinase A ( PKA) activity. By preventing the cAMP elevation, Famotidine restricts the stimulus to the H^+/ K^+- ATPase (Proton Pump).

The outcome of this molecular interference is a sustained reduction of hydrochloric acid ( HCl) secretion, particularly the basal and nocturnal output, resulting in a change in the concentration of acid within the gastric environment.

Official Administration Guidelines

Ulcerid, which contains the active ingredient Famotidine, is administered via two official routes: Oral (tablets or suspension) and Intravenous (IV) (injection or infusion). The IV route is officially designated for short-term use in hospitalized patients who are unable to take oral medication.

Tablets and suspensions may be taken with or without food. Oral administration is commonly scheduled either once daily at bedtime or twice daily (morning and bedtime), depending on the specific condition being addressed.

---

Standard Labeled Dosing Regimens (Adults)

Condition	Standard Adult Regimen	Official Duration
Active Duodenal Ulcer	40 mg once daily OR 20 mg twice daily	Up to 8 weeks
Erosive Esophagitis	20 mg to 40 mg twice daily	Up to 12 weeks
Risk Reduction of Ulcer Recurrence	20 mg once daily	1 year or as clinically indicated
Pathological Hypersecretory Conditions	Starting at 20 mg every 6 hours (Max 160 mg every 6 hours)	As clinically indicated

---

Administration Instructions for Specific Populations

Renal Impairment: For adult patients with moderate to severe renal impairment (creatinine clearance < 50 mL/min or < 60 mL/min), a reduction in the daily dose by 50% or an extension of the dosing interval (e.g., to 36 to 48 hours) is formally required. The specific adjustment depends on the degree of impairment and the indication.

Pediatric Use: For children weighing less than 40 kg, the 20 mg and 40 mg tablet strengths are generally not recommended due to required lower doses, and an alternate formulation (e.g., oral suspension) is specified for use. Dosage in this population is typically weight-based (mg/kg).

Intravenous Administration: The IV injection must be administered slowly, typically over at least 2 minutes, or as an infusion over 15 to 30 minutes.

Research evidence / Overview of studies

Overview of Efficacy

The intervention’s scope in recent clinical trials

Research has explored studies that evaluated whether the intervention was associated with changes in patient outcomes and symptom severity, noting the time course for the initial observed changes. The primary goal of the clinical program was to evaluate whether the intervention might modulate disease progression over a six-month period compared to a placebo.

Overall, the evidence requires further investigation and currently suggests a potential association with disease activity, though this was not observed in all participants. Results from Phase 3 trials have been published in peer-reviewed medical journals, focusing on primary endpoints related to symptom severity and quality of life.

Some studies examined the intervention’s profile when used as a single agent.

---

Combination Use and Research Focus

Research scope in advanced disease

Research has investigated whether this combination therapy influences the prognosis for people with advanced stages. Studies evaluated the intervention's possible association with inflammation and joint damage. Findings from a study in a small cohort suggested that the combination may be associated with changes in certain biomarkers.

Adverse events and specific populations

Studies have examined the potential interaction between alcohol consumption and this intervention, noting that some participants reported severe side effects. Adverse events most commonly observed in trials included mild nausea, headache, and fatigue.

Studies have examined the study findings related to adverse events and tolerability of this intervention in individuals with liver dysfunction. A key meta-analysis evaluated whether this treatment may differ from older therapies in long-term control. Researchers continue to evaluate the long-term study findings related to adverse events and tolerability of the intervention.

Key Studies & References A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) (Example Long-term Safety Trial)

Common questions about Ulcerid (FAQ)

---

Q: Is Ulcerid safe for long-term use?

Long-term use of Ulcerid is generally considered manageable, but individual patient responses vary. The prescribing physician is the source for monitoring for any potential delayed effects, such as changes in liver function, as part of the overall treatment plan. The safety profile is determined by clinical trial data and regulatory labeling.

---

Q: Can I stop taking Ulcerid suddenly if I feel better?

It is generally not recommended to stop this medication suddenly. Stopping abruptly may lead to potential discontinuation or rebound effects, depending on the drug. Any changes to the medication schedule, including stopping treatment, should be discussed with a healthcare professional. A healthcare provider can determine the appropriate schedule for gradually adjusting the dosage, if necessary, as following their guidance is important for minimizing risks during treatment adjustments.

---

Q: What is the best time of day to take Ulcerid?

According to product information, taking the medication in the morning with food may support its absorption. Consistency in the time of day and administration with a meal is typically recommended to maintain steady levels in the body. Patients who miss a dose should refer to the instructions provided by their pharmacist or prescribing physician for guidance on how to proceed.

How to Store and Dispose of Ulcerid (Famotidine)

Ulcerid must be stored according to official regulatory specifications to maintain its stability and effectiveness.

️ Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, 20 to 25 C (68 to 77 F). Do not store above 25 C in some regions.
Protection	Keep away from excess heat, moisture, and direct light. The oral liquid must not be frozen.
Container	Keep in the original container and ensure it is tightly closed.
Stability	Any unused oral suspension must be discarded after 30 days of preparation. Do not use past the labeled expiry date.

️ Disposal and Safety

Keep the medicine out of the reach and sight of children. For disposal, follow the instructions from your national health authority. This often involves either using an official drug take-back program or following guidelines to dispose of the product in the household trash, while avoiding disposal via wastewater.